[1]张南,夏杰,邓国宏,等.拉米夫定对慢性重型乙型肝炎患者生存率的提高[J].陆军军医大学学报(原第三军医大学学报),2008,30(01):75-77.
 ZHANG Nan,XIA Jie,DENG Guo-hong,et al.Effect of lamivudine on survival rate of patients with chronic severe hepatitis B[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(01):75-77.
点击复制

拉米夫定对慢性重型乙型肝炎患者生存率的提高(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
30卷
期数:
2008年第01期
页码:
75-77
栏目:
论著
出版日期:
2008-01-15

文章信息/Info

Title:
Effect of lamivudine on survival rate of patients with chronic severe hepatitis B
作者:
张南夏杰邓国宏王宇明
第三军医大学西南医院全军感染病研究所
Author(s):
ZHANG Nan XIA Jie DENG Guo-hong WANG Yu-ming
Department of Infectious Diseases, Southwest Hospital, Third Military Medical University
关键词:
拉米夫定慢性重型乙型病毒性肝炎预后生存率
Keywords:
lamivudine treatment prognosis survival rate
分类号:
R195.4; R512.62; R975.5
文献标志码:
A
摘要:
目的  观察抗病毒药物拉米夫定对慢性重型乙型病毒性肝炎患者生存率的影响。  方法  采用配对的回顾性队列研究方法,对1999年10月至2003年12月住院的慢性重型乙型病毒性肝炎患者,根据年龄、性别和病程3个变量对应用拉米夫定和未用拉米夫定治疗的患者进行匹配,比例为1∶1。配对结果为拉米夫定治疗组103例,未用拉米夫定组103例。对研究对象进行随访并比较两组中位生存时间及生存率的差别。  结果  拉米夫定治疗组中位生存时间为85 d,3年生存率为42.7%;未用拉米夫定组中位生存时间为35 d,3年生存率为23.4%,两组之间生存率有明显差异(P<0.01)。  结论  应用拉米夫定治疗可提高慢性重型乙型病毒性肝炎患者的生存率。
Abstract:
Objective  To investigate the survival rate of patients with chronic severe hepatitis B (CSH) after lamivudine treatment.   Method  A matched retrospective cohort study using data on patients derived from a prospectively collected chronic severe hepatitis B database was conducted. The database included patients who received or did not receive lamivudine treatment from October, 1999 to December, 2003. The match was conducted according with 3 variables: sex, age and duration of disease. The match ratio was 1∶1. Cases were patients who received lamivudine treatment (n=103).Controls were patients who did not receive lamivudine treatment (n=103).  All the patients were followed up and their median survival time and survival rate were compared and evaluated.   Results  The median survival time in lamivudine treatment group and control group were 85 and 35 d respectively. The survival rate for 3 years in treatment group and control group were 42.7% and 23.4% respectively. There was significance difference in survival rate between the 2 groups (P<0.01).   Conclusion  Lamivudine may improve survival of patients with chronic severe hepatitis B.

相似文献/References:

[1]李孟英,李玲,毛青.肾移植术后患者慢性重型乙型肝炎的分析及处理[J].陆军军医大学学报(原第三军医大学学报),2005,27(12):1309.
[2]郭建琼,程玲,刘洪利,等.163例慢性重型乙型病毒性肝炎合并自发性细菌性腹膜炎的临床分析[J].陆军军医大学学报(原第三军医大学学报),2011,33(21):2240.
 Guo Jianqiong,Cheng Ling,Liu Hongli,et al.Clinical analysis of 163 chronic severe viral hepatitis B patients complicated with spontaneous bacterial peritonitis[J].J Amry Med Univ (J Third Mil Med Univ),2011,33(01):2240.
[3]肖吉,陈文,刘玉元,等.拉米夫定治疗HBeAg阴性慢性乙型肝炎疗效相关因素分析[J].陆军军医大学学报(原第三军医大学学报),2011,33(08):835.
 Xiao Ji,Chen Wen,Liu Yuyuan,et al.Analysis of factors related to lamivudine efficacy in treating HBeAg-negative chronic hepatitis B[J].J Amry Med Univ (J Third Mil Med Univ),2011,33(01):835.
[4]张耀,郑莎,周吉军,等.拉米夫定治疗乙型肝炎病毒相关性肝衰竭疗效的Meta分析[J].陆军军医大学学报(原第三军医大学学报),2008,30(09):848.
 ZHANG Yao,ZHENG Sha,ZHOU Ji-jun,et al.Efficacy of lamivudine in treatment on HBV-related liver failure:Meta analysis study[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(01):848.
[5]李玲,毛青,黄燕萍,等.慢性乙型肝炎患者HBV DNA YMDD变异的检测及意义[J].陆军军医大学学报(原第三军医大学学报),2005,27(02):167.
[6]何登明,毛青,王宇明,等.拉米夫定疗程中慢性乙型肝炎患者血清IL-12水平和Th平衡变化及其意义[J].陆军军医大学学报(原第三军医大学学报),2004,26(19):0.[doi:10.16016/j.1000-5404.2004.19.028 ]
 HE Deng-ming,MAO Qing,WANG Yu-ming,et al.[J].J Amry Med Univ (J Third Mil Med Univ),2004,26(01):0.[doi:10.16016/j.1000-5404.2004.19.028 ]
[7]黄燕萍,王宇明.拉米夫定治疗50例慢性乙型肝炎患者自身前后对照试验[J].陆军军医大学学报(原第三军医大学学报),2002,24(11):0.[doi:10.16016/j.1000-5404.2002.11.055 ]
 HUANG Yan ping,WANG Yu ming.[J].J Amry Med Univ (J Third Mil Med Univ),2002,24(01):0.[doi:10.16016/j.1000-5404.2002.11.055 ]

更新日期/Last Update: 2008-05-05